Chronic Kidney Disease and Post-Percutaneous Coronary Intervention Mortality in Patients With Left Main and Equivalent Coronary Artery Disease.
| Autor: | Yager N; Division of Cardiology and Nephrology, Albany Medical College, Albany, New York., Hongalgi K; Division of Cardiology and Nephrology, Albany Medical College, Albany, New York., Torosoff M; Division of Cardiology and Nephrology, Albany Medical College, Albany, New York. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Texas Heart Institute journal [Tex Heart Inst J] 2022 Sep 01; Vol. 49 (5). |
| DOI: | 10.14503/THIJ-21-7670 |
| Abstrakt: | Background: Patients with chronic kidney disease are underrepresented in registries and in randomized trials of coronary artery disease management. To investigate effects of chronic kidney disease on outcomes of nonemergent percutaneous coronary intervention in patients with left main or left main-equivalent coronary artery disease, we analyzed data from the New York State Percutaneous Coronary Intervention Registry during the calendar year 2015, involving 2,956 elective percutaneous coronary intervention cases. Outcomes of percutaneous coronary intervention in patients with various degrees of chronic kidney disease and stable left main or left main-equivalent coronary artery disease were compared. Methods: Only patients with left main or left main-equivalent coronary artery disease and elective percutaneous coronary intervention were included in the study cohort. Patients with acute coronary syndromes within 24 hours of the index percutaneous coronary intervention, patients reported to be in shock, and patients with prior coronary artery bypass surgery were excluded from the study cohort. Results: In this cohort, stage 4 or 5 chronic kidney disease, current congestive heart failure, and left main disease remained statistically significant predictors of post-percutaneous coronary intervention mortality. Conclusion: Our findings in this large, statewide cohort indicate that advanced kidney disease is associated with markedly increased post-nonemergent percutaneous coronary intervention mortality. (© 2022 by the Texas Heart® Institute, Houston.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|